11 completed, 1 withdrawn. 12 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Completed 11, Withdrawn 1 |
Follow Affiris AG: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Follow-up Study to Assess a Second Boost Immunization With AFFITOPE® PD01A With Regard to Safety and Clinical Activity (AFF008AA) AFFITOPE® PD01A - Parkinson's Disease | Phase 1 | Completed | Affiris AG | 26 | 2016-02-02 | 2017-06-05 |
| Study Assessing Safety, Immunogenicity and LDLc -Lowering Activity of 2 PCSK9 Targeting AFFITOPE Vaccines in Healthy Subjects AFFITOPE® AT04A+adjuvant, AFFITOPE® AT06A+adjuvant, Adjuvant without active component - Hypercholesterolemia | Phase 1 | Completed | Affiris AG | 72 | 2015-07-01 | 2017-10-20 |
| Study Assessing Safety and Therapeutic Activity of AFFITOPE® PD01A and PD03A in Patients With Early MSA AFFITOPE® PD01A + Adjuvant, AFFITOPE® PD03A + Adjuvant, Adjuvant without active component - Multiple System Atrophy, Neurodegenerative Diseases | Phase 1 | Completed | Affiris AG | 30 | 2014-12-11 | 2017-06-05 |
| Study Assessing Tolerability and Safety of AFFITOPE® PD03A in Patients With Early Parkinson's Disease Low dose AFFITOPE® PD03A + Adjuvant, High dose AFFITOPE® PD03A + Adjuvant, Adjuvant without active component - Parkinson Disease, Neurodegenerative Diseases | Phase 1 | Completed | Affiris AG | 36 | 2014-12-01 | 2016-10-31 |
| Follow-up Study to Assess One Boost Immunization With AFFITOPE® PD01A With Regard to Safety and Clinical Activity AFFITOPE® PD01A, Control - Parkinson's Disease | Phase 1 | Completed | Affiris AG | 28 | 2014-08-01 | 2015-08-17 |
| Tolerability and Safety of Subcutaneous Administration of Two Doses of AFFITOPE® PD01A in Early Parkinson's Disease AFFITOPE® PD01A, Control - Parkinson's Disease | Phase 1 | Completed | Affiris AG | 32 | 2012-02-01 | 2015-08-17 |
| Safety, Immunogenicity and Dose Response of ATH03, a New Vaccine Against the Cholesterol Ester Transfer Protein (CETP) ATH03 - HDL, Drug Safety | Phase 1 | Completed | Affiris AG | 36 | 2011-05-01 | 2012-10-05 |
| Safety and Tolerability of AFFITOPE AD03 AFFITOPE AD03, AFFITOPE AD03 + Alum - Alzheimer's Disease | Phase 1 | Completed | Affiris AG | 28 | 2010-10-01 | 2011-12-20 |
| Safety/Tolerability, Immunological and Clinical Activity of a Boost Immunization With AFFITOPE AD02 AFFITOPE AD02 - Alzheimer's Disease | Phase 1 | Completed | Affiris AG | 20 | 2009-10-01 | 2010-10-19 |
| Tolerability and Safety of Subcutaneous Administration of AFFITOPE AD02 in Mild to Moderate Alzheimer's Disease AFFITOPE AD02 - Alzheimer's Disease | Phase 1 | Completed | Affiris AG | 24 | 2008-02-01 | 2010-10-19 |
| Tolerability and Safety of Subcutaneous Administration of Affitope AD01 in Mild to Moderate Alzheimer's Disease AFFITOPE AD01, AFFITOPE AD01 adjuvanted - Alzheimer's Disease | Phase 1 | Completed | Affiris AG | 24 | 2007-07-01 | 2010-10-19 |
| Study Assessing Tolerability and Safety and Exploring the Immunogenicity and Therapeutic Activity of AFFITOPE® PD01A in PD-GBA Patients AFFITOPE® PD01A + Adjuvant, Adjuvant without active component - Parkinson's Disease | Phase 1 | Withdrawn | Affiris AG | 2016-08-05 |
Parkinson Disease (5) · Alzheimer Disease (4) · Neurodegenerative Diseases (2) · Hypercholesterolemia (1) · Inhibition, Psychological (1) · Multiple System Atrophy (1)
Adjuvants, Pharmaceutic (4) · aluminum sulfate (1)
Austria (10) · France (1) · Germany (1)
Dieter Volc, Prim. Dr. (2) · Achim Schneeberger, MD (1) · Dieter Volc, Prim, Dr. (1) · Margot Schmitz, Univ. Doz. (1) · Margot Schmitz, Univ. Doz. Dr. (1) · Markus Zeitlinger, MD (1) · Siegfried Kasper, MD (1) · Thomas Gasser, Prof. Dr. (1) · Wassilios Meissner, MD, PhD (1) · Werner Poewe, MD (1)
PMID 30741694, PMID 32882100, PMID 33969434
2014 (3), 2015 (2), 2016 (1)